BarMatinTM in Canada authorized (confined permission):The Canadian Food Inspection Agency (CFIA) has permitted BarMatinTM according to Directive 2000-07 for outdoor trials in Canada in the provinces Saskatchewan and Manitoba (no. 25-AGQ1-406-BAR). With the resulting biosafety assessment data an unconfined permission according to Directive 94-08 will be submitted.
Preclinicial study proved: Thaumatin has a preventive effect against gastric cancer:
80 % of all human beings carry the bacteria Helicobacter pylori inside their gastrointestinal tract and therefore have an increased risk for suffering on gastric cancer, which has a high mortality rate. Effective vaccination is currently not possible or only with strong side effects.
Digested peptides from thaumatin efficiently inhibit the Helicobacter pylori-induced release of the metastases-associated pro-inflammatory cytokine IL-17A via blocking the bitter taste intra-gastrointestinal receptor TAS2R16 (reduction is about 90 %), which plays a key role during cancer pathogenesis. Thus, thaumatin has, beyond its excellent sweetening features, a huge potential as a prophylaxis against gastric cancer development even in very low intake dosages (see Richter et al., (2024) Gastric digestion of the sweet-tasting plant protein thaumatin releases bitter peptides that reduce H. pylori induced pro-inflammatory IL-17A release via the TAS2R16 bitter taste receptor. Food Chem (448): 1-10).
You are coming from the food, plant breeding, beverage or pharmaceutical industry and have interest on BarMatinTM?
Contact us soon!
We answer to all inquiries immediately and discretely! We are pleased for your interest!
